Skip to main content

Immunosuppression by breast cancer associated p43-effect of immunomodulators

Breast Cancer Research and Treatment volume 41, pages 171–176 (1996)Cite this article

Summary

It has been previously shown that p43 — a breast cancer associated antigen — has immunosuppressive properties. The present study was carried out in order to elucidate the pathomechanisms of immunosuppression in breast cancer patients influenced by the expression of p43. Lymphocytes were cultured from blood of 29 women with benign lesions in the breast as well as from 41 female patients with breast cancer. Lymphocyte stimulation was performed by addition of Concanavalin (Con A) in cultures with lymphocytes alone (CONLYM) or in lymphocytes incubated with p43 (CONAg). In other series immunomodulation was tried by addition of indomethacin (INDLYM, INDAg), levamisole (LEVLYM, LEVAg), or interleukin-2 (ILLYM, ILAG). In breast cancer patients, addition of p43 significantly inhibited the activation of lymphocyte proliferation by Con A compared to women with benign tumors. The addition of indomethacin or levamisole did not influence this inhibitory effect of p43 in breast cancer patients. Contrary to these observations, addition of IL-2 resulted in increased proliferation of lymphocytes from patients with benign as well as malignant tumors, which was inhibited after addition of p43. Analysis of the correlation of the immunosuppressive properties of p43 in correlation with prognostic factors for breast cancer showed evidence for a stronger activity of p43 in early stage tumors (i.e. smaller than 2 cm, lymph node negative, histologic grading GI), confirming previous observations of a higher expression of p43 in early stages of breast cancer.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Moroz C, Giler SH, Kupfer B, Urca I: Lymphocytes bearing surface ferritin in patients with Hodgkin's disease and breast cancer. N Engl J Med 298: 1175–1176, 1977

    Google Scholar 

  2. Moroz C, Bessler H: Ferritin as a marker in malignancy. In: De Sousa M, Brock J (eds) Iron in Immunity, Cancer and Inflammation. Wiley, New York, 1989, pp 283–301

    Google Scholar 

  3. Maymon R, Bahari C, Moroz C: Placental isoferritin measured by a specific monoclonal antibody as a new predictive marker for premature contractions. Obstet Gynecol 74: 597–599, 1989

    PubMed  Google Scholar 

  4. Hahn HWL, Stahlhut MW, Chung L: Inhibitory effects of isoferritins from tumour and non-tumour tissue on E-rosettes formation. Lancet i: 43–44, 1984

    Google Scholar 

  5. Rosen HR, Stierer M, Göttlicher J, Wolf H, Weber R, Vogl E, Eibl M: Determination of placental ferritin (PLF)-positive lymphocytes in women in early stages of breast cancer. Int J Cancer 52: 229–233, 1992

    PubMed  Google Scholar 

  6. Whitehead RH, Roberts GP, Thatcher J, Teasdale C, Hughs LE: Masking of receptors for sheep erythrocytes on human T-lymphocytes by sera from breast cancer patients. J Natl Cancer Inst 58: 1573–1577, 1977

    PubMed  Google Scholar 

  7. Sirota L, Kupfer B, Moroz C: Placental isoferritin as a physiological downregulator of cellular immunoreactivity during pregnancy. Clin Exp Immunol 77: 257–262, 1989

    PubMed  Google Scholar 

  8. Rosen HR, Ausch C, Reiner G, Reinerova M, Svec J, Tüchler H, Schiessel R, Moroz C: Downregulation of lymphocyte mitogenesis by breast cancer-associated p43. Cancer Lett 82: 105–111, 1994

    PubMed  Google Scholar 

  9. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11: 359–364, 1957

    PubMed  Google Scholar 

  10. Stierer M, Rosen H, Weber R, Hanak H, Spona J, Tüchler H: Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Ann Surg 218: 13–21, 1993

    PubMed  Google Scholar 

  11. Sedlak J, Reinerova M, Hunakova L, Ausch C, Chorvath B, Rosen H, Moroz C: Alterations of cell surface antigens induced by placental isoform of ferritin in human carcinoma cell lines. Cancer Lett 94: 101–106, 1995

    PubMed  Google Scholar 

  12. Corty PE, Brando C, Shevach EM: CD59 functions as a signal-transducing molecule for human T cell activation. J Immunol 146: 4092–4096, 1991

    PubMed  Google Scholar 

  13. Halvorsen R, Gaudernack G, Leivestad T, Varidal F, Thorsby E: Activation of resting pure CD4- and CD8- cells via CD3. Requirements for second signals. Scand J Immunol 26: 197–202, 1987

    PubMed  Google Scholar 

  14. Halvorsen R, Leivestad T, Gaudernack G, Thorsby E: Accessory cell dependent T cell activation via Ti/CD3; involvement of CD2-LFA3 interactions. Scand J Immunol 28: 277–283, 1988

    PubMed  Google Scholar 

  15. Hunig T, Tiefenthaler G, Meyer zum Buschenfelde KH, Meuer SC: Alternative pathway activation of T cells by binding of CD2 to its cell surface ligand. Nature 326: 298–291, 1987

    PubMed  Google Scholar 

  16. Meuer SC, Meyer zum Buschenfelde KH: T cell receptor triggering induces responsiveness to interleukin 1 and interleukin 2 but does not lead to T cell proliferation. J Immunol 136: 4106–4110, 1986

    PubMed  Google Scholar 

  17. Rosen HR, Moroz C, Reiner A, Reinerova M, Stierer M, Svec J, Schemper M, Jakesz R: Placental isoferritin associated p43 antigen correlates with features of high differentiation in breast cancer. Breast Cancer Res Treat 24: 17–26, 1992

    PubMed  Google Scholar 

  18. Rosen HR, Stierer M, Göttlicher J, Wolf H, Spoula H, Eibl M: Determination of placental ferritin-positive peripheral lymphocytes in early stages of breast cancer. Am J Surg 165: 213–217, 1993

    PubMed  Google Scholar 

  19. Haynes BP, Fauci AS: Introduction to clinical immunology. In: Brunwald E, Isselbacher KJ, Petersdorf RG, Wilson JD, Martin MB, Fauci AS (eds) Harrison's Principles of Internal Medicine. McGraw-Hill Book Company, New York, pp 328–337, 1986

    Google Scholar 

  20. Möller G: Elimination of allogeneic lymphoid cells. Immunol Rev 73: 5–160, 1983

    PubMed  Google Scholar 

  21. Griffin FM Jr: Mononuclear cell phagocytic mechanisms and host defense. In: Gallin JI, Fauci AS (eds) Advances in Host Defense Mechanisms: Volume I: Phagocytic Cell. Raven Press, New York, pp 31–55, 1982

    Google Scholar 

Download references

Author information

Affiliations

  1. Associate Professor of Surgery, Ludwig Boltzmann Research Institute for Surgical Oncology, Vienna, Austria

    Harald R. Rosen, Christoph Ausch, Georg Reiner & Rudolf Schiessel

  2. Slovak Academy of Sciences, Bratislava, Slovak Republic

    Martha Reinerova & Jurai Svec

  3. Ludwig Boltzmann Institute for Hematology and Oncology, Vienna, Austria

    Heinz Tüchler

  4. Department of Immunology, Beilinson Medical Center, Petah Tikva, Israel

    Chaya Moroz

Authors
  1. Harald R. Rosen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christoph Ausch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Georg Reiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Martha Reinerova
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jurai Svec
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Heinz Tüchler
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rudolf Schiessel
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Chaya Moroz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Rosen, H.R., Ausch, C., Reiner, G. et al. Immunosuppression by breast cancer associated p43-effect of immunomodulators. Breast Cancer Res Tr 41, 171–176 (1996). https://doi.org/10.1007/BF01807162

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01807162

Key words

  • breast cancer
  • immunosuppression
  • lymphocytes
  • p43